title: Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
abstract: Over the past decade, the safety and efficacy of the anti-CD20 antibody rituximab has resulted in its use in virtually all patients with B-cell non-Hodgkin's lymphoma (NHL). Unfortunately, many patients who initially benefit from rituximab develop resistance while others may never respond. Both the successes and limitations of rituximab have heralded an explosion in research and development of novel monoclonal antibodies. Strategies employed to improve upon rituximab have included developing antibodies to target new epitopes of CD20 and new antigens, humanizing or creating fully human antibodies, and engineering antibodies with a potentially greater capacity for interaction with the host immune system. Each of these strategies has shown varying degrees of preclinical and clinical success. In this review we discuss the rationale for various strategies and report results from clinical trials employing these agents.
authors.affiliation: Center for Lymphoma and Myeloma, Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Martin
authors.forename: Richard R
authors.initials: RR
authors.lastname: Furman
authors.forename: Jia
authors.initials: J
authors.lastname: Ruan
authors.forename: Rebecca
authors.initials: R
authors.lastname: Elstrom
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Barrientos
authors.forename: Ruben
authors.initials: R
authors.lastname: Niesvizky
authors.forename: Morton
authors.initials: M
authors.lastname: Coleman
authors.forename: John P
authors.initials: JP
authors.lastname: Leonard
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D018951:Antigens, CD20 / Q000276:immunology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology*; D018122:B7-1 Antigen / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D000069283:Rituximab; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D018951:Antigens, CD20; D000944:Antigens, Differentiation, B-Lymphocyte; D000951:Antigens, Neoplasm; D018122:B7-1 Antigen; D019013:CD40 Antigens; D015507:Drugs, Investigational; D051918:Sialic Acid Binding Ig-like Lectin 2; D000069283:Rituximab